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Abstract
Background: Recent trends to earlier access to anti-retroviral treatment underline the importance of accurate HIV
diagnosis. The WHO HIV testing strategy recommends the use of two or three rapid diagnostic tests (RDTs)
combined in an algorithm and assume a population is serologically stable over time. Yet RDTs are prone to cross
reactivity which can lead to false positive or discordant results. This paper uses discordancy data from Médecins
Sans Frontières (MSF) programmes to test the hypothesis that the specificity of RDTs change over place and time.
Methods: Data was drawn from all MSF test centres in 2007-8 using a parallel testing algorithm. A Bayesian
approach was used to derive estimates of disease prevalence, and of test sensitivity and specificity using the
software WinBUGS. A comparison of models with different levels of complexity was performed to assess the
evidence for changes in test characteristics by location and over time.
Results: 106, 035 individuals were included from 51 centres in 10 countries using 7 different RDTs. Discordancy
patterns were found to vary by location and time. Model fit statistics confirmed this, with improved fit to the data when
test specificity and sensitivity were allowed to vary by centre and over time. Two examples show evidence of
variation in specificity between different testing locations within a single country. Finally, within a single test centre,
variation in specificity was seen over time with one test becoming more specific and the other less specific.
Conclusion: This analysis demonstrates the variable specificity of multiple HIV RDTs over geographic location and
time. This variability suggests that cross reactivity is occurring and indicates a higher than previously appreciated risk
of false positive HIV results using the current WHO testing guidelines. Given the significant consequences of false
HIV diagnosis, we suggest that current testing and evaluation strategies be reviewed.
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Introduction
The UNAIDS strategy “Getting to Zero” is an ambitious
programme to reduce to zero both the number of new HIV
infections and AIDS related deaths[1]. Recent evidence that
treatment can prevent transmission of disease, along with a
gathering consensus that anti-retroviral treatment (ART) should
be started earlier during the asymptomatic stage of HIV,
underlines the importance of increasing access to HIV testing
[2,3]. New WHO guidelines on counseling and testing now
discuss self-testing strategies for the first time [4]. These
developments increase the need for accurate HIV testing.
The WHO HIV testing strategy recommends the use of rapid
diagnostic tests (RDTs) combined in an algorithm of two or
three tests for the diagnosis of HIV in resource limited settings
[4]. HIV RDTs are susceptible to cross reactivity with non-HIV
antibodies and this can lead to discordant (one test positive,
one test negative) and false positive results (both tests falsely
positive).
The CDC/WHO/APHL “Guidelines for Appropriate Evaluation
of HIV Testing Technologies in Africa” provide a 3 stage
system for development of a diagnostic HIV RDT algorithm [5].
After a review of the RDTs from published data, an evaluation
of the RDTs chosen is done using a sample serobank followed
by pilot testing in the field and then ongoing monitoring of
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testing quality. However implementation of these guidelines is
generally beyond the capacity of most programmes and in
many cases tests are introduced and algorithms formulated
without preceding local validation [6].
Furthermore the guidelines assume that a population is
serologically stable over time, as once adequate test
performance is established through the initial validation, no
ongoing assessment of test specificity or sensitivity is required.
Our experience across more than 22 programmes in 10
countries, suggest that this is not the case. This paper uses
discordancy data from Médecins Sans Frontières - Operational
Centre Amsterdam (MSF) testing programmes to test the
hypothesis that the specificity of RDTs change over time and
place.
Methods
Inclusion Criteria
Data was drawn from HIV test centres where MSF offered
access to free counselling and testing (CT) services as part of
its routine programmes in 2007-8. All centres reported monthly
testing volumes, HIV positivity rates, and rates and patterns of
discordancy. Test centres were included if an algorithm was
used where two independent RDTs were used in parallel for all
persons tested, and if at least 3 months of data representing
>90 patient/client results was reported.
Quality control
Tests were performed according to MSF standard operating
procedures (SOPs) based on the manufacturer’s instructions.
All rapid test kits were stored according to manufacturers'
instructions. Tests were performed by trained counsellors or
nurses. Quality control for the test device was performed using
a weak-positive sample prepared by the MSF supervising
laboratory on each new test kit, and at least once weekly.
Quality control for correct execution and interpretation of the
test was performed in the laboratory by repeat testing of a
random sample of 20 positive and 20 negative samples each
month. Invalid test results whereby the control line did not
appear were discarded, and repeated on a new test device. As
an additional quality control measure, all positive or discordant
results were repeated in the laboratory by a technician on a
venous sample. Efforts were made to blind the technician to
the results of the first tests. Where there was discrepancy
between the results of the counsellor/nurse and the laboratory,
the test was repeated a third time in the laboratory to determine
the final outcome using a test from a different test kit and
where possible from a different batch.
Analysis
In the absence of reference laboratory testing to assess false
positive and false negative results, a Bayesian approach was
used to derive estimates of disease prevalence, and of test
sensitivity and specificity using the software WinBUGS. This
approach allows calculation of test characteristics without a
gold standard for comparison by specifying equations linking
prevalence, specificity and sensitivity to data [7], [8], [9].
Logistic transforms were used to ensure that the distributions
for parameters lay between 0 and 1. Prior distributions for
prevalence were uninformative, while sensitivity and specificity
parameters were given priors with median value 0.99, and
credible interval (0.24, 1.0) to incorporate prior knowledge on
the likely values for these test statistics. A comparison of
results with uninformative priors gave broadly consistent
output, but led to convergence difficulties in some cases.
There are four possible test results for each individual,
namely: both tests positive, test A positive and test B negative,
test A negative and test B positive, and both tests negative. For
each location, and each month, we estimated disease
prevalence (p), sensitivity (vA, vB) and specificity (fA, fB) of the
two tests using formulae that define the probability of these four
test results. For example, the probability of two positive test
results is:
Probability (positive,positive) = p*vA*vB + (1-p)*(1-fA)*(1-fB)
and the number of individuals with two positive tests has a
binomial distribution with N equal to the total number of
individuals tested, and the event probability as above. Since
dependencies in the data prevent estimation of all parameters
independently, we included a further association between
sensitivity and specificity to ensure convergence of the full
model. Details of the choice of this assumption, together with a
detailed listing of all model equations are provided as
Supporting Information (see Annexe S1 and Figure S1).
Model Selection
To assess the variation in algorithm results across different
programmes and over time within the same programme, we
compared model fit statistics for a sequence of models with
increasing numbers of parameters. All models estimated
prevalence at each site independently. The simplest model
(Model 0) assumed that all tests have the same sensitivity and
specificity. Model 1 allowed for each test to have a different
specificity and sensitivity, but assumed this is fixed over
locations. Model 2 included variability in test characteristics by
location, while Model 3 also included variability over time. We
used the Deviance Information Criterion (DIC) within WinBUGS
to compare model fit, with smaller values of the DIC indicating
better fit. The best-fit model was then used to assess whether
variation in specificity over time and place within a single
country and /or site was likely to be of value in predicting
discordancy rates.
In order to assess the roles of sensitivity and specificity in
discordant results, we used the estimated values of test
sensitivity (vA and vB) and test specificity (fA and fB) in each
location – together with the prevalence and the total number of
tests – to predict the proportion of discordant results that were
due to false positives and false negatives.
In light of findings that most discordant results were due to
false positives, we developed an alternative ‘perfect sensitivity’
model in which we assume all discordant results are due to
false positives. That is, we assume vA = vB = 1 at all locations.
While not used for any of the main results in this paper, this
alternative model allows us to assess the impact of model
assumptions on our results.
Variable Specificity of HIV Rapid Diagnostic Tests
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Ethics Statement
This analysis met the criteria set by the Médecins Sans
Frontières Ethics Review Board, for retrospective analysis of
routinely collected programmatic data. Data used in this
analysis are aggregate data without personal identifiers and
therefore individual patient consent was not obtained.
Results
106,035 individuals comprising a total of 212,070 tests, were
included from 51 centres in 10 countries. Determine® was
used for all testing together with Capillus®, Hexagon®, First
Response®, SD Bioline®, Tridot® and Unigold®. A summary
of countries, test performed, discordancy rates and patterns of
discordancy is given in Table 1. HIV prevalence by test site
within each country can be found in the Information (see Figure
S2). A break-down of the number of tests done in each test
centre is available in the Information (Annexe S2).
Several of the test centres experienced considerable
variability in the pattern of discordancy (testA+/testB- versus
testA-/testB+) as shown in Figures 1 and 2.
Table 1. Overview of countries and patients tested.
Country Second test Patients tested Total discordant Percentage Determine® +1
CAR Unigold® 4, 329 143 (3.3%) 92%
Congo-B Unigold® 438 26 (5.9%) 46%
DRC Unigold® 19, 065 119 (0.6%) 74%
Ethiopia Unigold® 4, 961 363 (7.3%) 15%
Haiti Unigold® 2, 006 20 (1.0%) 95%
 Capillus® 4, 458 54 (1.2%) 100%
India Unigold® 1, 193 19 (1.6%) 58%
 TriDot® 4, 266 59 (1.4%) 97%
Ivory Coast Unigold® 3, 386 125 (3.7%) 90%
 Hexagon® 5, 648 334 (5.9%) 39%
Myanmar Unigold® 14, 796 331 (2.2%) 90%
 Capillus® 25, 024 528 (2.1%) 73%
Uganda Unigold® 6, 056 129 (2.1%) 81%
Zimbabwe First Response® 7, 782 18 (0.2%) 67%
 SD Bioline® 2, 627 11 (0.4%) 73%
1 Refers to the percentage Determine® test positive amongst the discordant tests.
doi: 10.1371/journal.pone.0081656.t001
Figure 1.  Discordancy pattern in Kachin, Myanmar test centre using Determine® and Capillus®.  
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Model Comparison
Table 2 describes the sequence of models fit to data
together with the Deviance Information Criterion (DIC) statistic
used to measure the strength of model fit, with smaller
numbers indicating an improvement in fit. The large intervals
between the DIC numbers give strong support for the inclusion
of additional factors, providing clear evidence of a better fit to
the data when variability by place and variability over time are
included in the model.
Variation by geographical location
We show evidence of variation in test characteristics by
place using the estimated specificity of Determine® and
Unigold® (the most commonly used tests in the dataset) at
different sites in two countries: Ethiopia and Myanmar. Figure 3
shows point estimates and 95% credible intervals for the
estimates of specificity at each test site in each of 6 test sites in
Ethiopia, and 13 sites in Myanmar. By estimating all
parameters simultaneously, we have ensured that estimates of
specificity are adjusted for disease prevalence and test
sensitivity by test site. Determine® was found to perform well in
all sites in Ethiopia, but shows variable specificity in Myanmar,
with specificity at one site as low as 92.6%. In contrast,
Unigold® performs well in Myanmar but poorly in Ethiopia, with
point estimates of specificity below 93% at a number of sites.
Further examples of variable specificity by location can be
found in the Information (see Figure S3).
The data provide evidence of variation in test specificity
between different testing locations within a single country.
Variation in the same programme over time
We demonstrate variation in individual test specificity over
time using a site in Myanmar and another in Ethiopia as
examples. By focusing on individual sites, rather than pooled
estimates over an entire country, we avoid any artificial effects
resulting from varying prevalence between sites. The model
also includes independent estimates of prevalence at each
time point, to adjust for any changes in prevalence over the
time period. Figure 4 presents estimates and 95% credible
intervals for specificity of Determine® in Kachin in Myanmar,
and for specificity of Unigold® in Abdurafi in Ethiopia. These
two examples show clear evidence of changing specificity over
time within a single testing site, with one test becoming more
specific and the other less specific.
While these two programmes are not the only ones to show
temporal changes in specificity, it should be noted that not all
Figure 2.  Discordancy pattern in Mindouli, Congo-Brazzaville (Determine®, Unigold®).  
Table 2. Sequence of models fitted together with Deviance Information Criteria (DIC).
Model Description DIC
Model 0 All tests have equal sensitivity and specificity. 10, 028
Model 1 Sensitivity and specificity vary by test but not location or time. 9, 183
Model 2 Sensitivity and specificity vary by test and location but not time. 7, 576
Model 3 Sensitivity and specificity vary by test, location and time. 6, 149
This indicates goodness of fit of the model to data, with smaller values indicating a better fit.
doi: 10.1371/journal.pone.0081656.t002
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tests sites showed evidence of variation over time: some did
not have sufficient months of testing with the same test to
explore temporal changes, while others showed consistency in
test characteristics over time. The examples in Figure 4 have
been deliberately chosen to highlight the existence of variation
over time that is not exclusive to a single test, and is not either
a consistent improvement or decline in specificity.
Role of test sensitivity
The results presented here focus on changes in test
specificity by place and over time. To investigate the role of test
sensitivity in discordant results, we calculated the expected
proportion of discordant results due to false negatives. Over all
locations and months, we estimated that 9.9% of discordant
results were due to false negatives, with the remaining 90.1%
due to false positives. Countries with the highest proportion of
false negatives were India (38.4%) and Congo-Brazzaville
(32.2%). In India, these false negatives were largely driven by
low estimated sensitivity of Tridot®, while in Congo-Brazzaville,
sensitivity of Unigold® was estimated to be low. However, both
these estimates were made from small numbers of samples:
estimates in Congo-Brazzaville were made from only 10-50
Figure 3.  Estimates of specificity of Determine® and Unigold® in Ethiopia and Myanmar.  The dots show the point estimate
at a test site, and the bars give 95% credible intervals. All estimates are adjusted for site prevalence and test sensitivity. Note that
some sites in Myanmar used Capillus® as the second HIV test, so that the number of sites with estimates of Unigold® specificity is
fewer than the number of sites with estimates of Determine® specificity. The data included a median of 650 individuals per site
(range 101-1,901) in Ethiopia, a median of 1,358 individuals per site (range 193-15,094) tested using Determine® in Myanmar and a
median of 569 individuals per site (range 193-7,004) tested using Unigold® in Myanmar.
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monthly HIV tests, while uncertainty in estimates of test
sensitivity for Tridot® arose from data for a single country with
Figure 4.  Estimates of specificity of Determine® in Kachin, Myanmar and Unigold® in Abdurafi, Ethiopia.  
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relatively small numbers of discordant cases. Complete results
of the sensitivity analysis by country and test site are available
as Supporting Information (Figure S4).
As our best-fit model showed high sensitivity in almost all
locations, we also considered estimates from an additional
model that assumed perfect sensitivity of all tests. Using this
perfect sensitivity model, the estimates of prevalence and test
specificity were only slightly changed from the best fit model.
Almost all (around 96%) of the specificity estimates were within
1% of our previous estimates, with most of the big changes due
to small numbers of tests in Congo-Brazzaville. Our main
findings are unchanged in this model: our example sites in
Figure 4 still show clear variation in specificity over time, and
there are more sites indicating changes in test specificity over
time in this model than the best fit model. Further details on
these analyses are provided as Supporting Information (see
Annexe S1).
Discussion
The results demonstrate three key points regarding HIV
RDTs. Firstly, specificity varies by location, both within and
between countries. Secondly, specificity varies over time within
a particular location and thirdly these variations are not
confined to a single test.
Possible explanations for the variability in the discordancy
patterns seen in our data are changes in test performance (i.e.
sensitivity or specificity) or quality of testing. We have
controlled for differences due to quality of testing and for test
device failure by repeating all results in the laboratory, and
through a systematic quality control system. Changes in
sensitivity, either due to variations in the test’s ability to detect
early seroconversion or due to genetic HIV viral diversity are
other potential causes for discordancy. Our modelling however
allowed us to look at the effect of specificity while controlling for
changes in sensitivity and prevalence of HIV. Within the model,
both time and geographic location were important for
explaining these data. Sensitivity for most tests was good, with
the exception of Unigold® which showed considerable variation
and Tridot® in India. A comparison of our results with a model
assuming perfect sensitivity showed an adequate fit to the
data, and left our estimates of prevalence and test specificity
only marginally changed from the best-fit model. Given the high
estimates of sensitivity for most tests in most countries, and the
adequate fit of a model excluding variation in sensitivity, we
conclude that variation in test sensitivity plays little role in
explaining changes in discordant tests.  By allowing for variable
sensitivity in our full model, we have adjusted for any small
changes in discordancy patterns that could be attributable to
changing sensitivity.
We postulate that cross reactive antibodies are the most
likely cause of the variability in specificity in the MSF
programmes described in this paper. Cross reacting antibodies
react variously and unpredictably which is consistent with the
observed temporal changes within individual programmes, and
are likely to vary in prevalence between different population
groups [10,11]. Cross reactivity with non-specific polyclonal B-
lymphocyte antibodies formed in the early immune response
has been reported as a cause of HIV testing interference
[12–14] and this activity may be heightened in the resource-
limited settings in which MSF operates[14–16].
Geographic differences in the performance of HIV RDTs
have been previously documented, particularly for the Sub-
Saharan Africa region. The varying specificity has been most
commonly attributed to cross reactivity due to exposure to
infectious agents unique to the region such as malaria,
schistosomiasis, or helminth infections [17,18]. Further
investigations to determine if specific infections are more likely
to cross-react with HIV serological tests, either directly or
indirectly, have produced mixed results in identifying a single
agent as responsible [12,19–22]. It is possible that variable
antigenic exposure may explain some of both the geographic
and temporal changes we found in our study, due to differing
geographic or seasonal prevalence of an infectious agent or
agents. We were unable to demonstrate a seasonal change
over time due to lack of precise information on seasonality for
all test centres and insufficient longitudinal data. Similarly due
to lack of data on co-infections we were unable to draw any
links between disease exposure at different test sites and our
findings of varying specificity.
Interestingly, researchers in Tanzania report evidence of
geographic variability in specificity of the Determine® test but
not Statpak® in the South West region of the country. They
found an increased false positivity rate in low altitude regions
but were unable to link this with specific infections such as
malaria or schistosomiasis. They speculate that humoral
immune responses against infections known to be more
prevalent in lower altitudes could be responsible for their
results [20].
A further possibility that may explain why cross reactivity
would vary over time and place is that of population
movements due to migration or displacement, both of which
are common in resource limited settings. Displaced persons
may have an increased vulnerability to infections such as
malaria or schistosomiasis in a new location and may be in
poorer health than residents.
The result of our analysis suggest that the current guidelines
and practice of selecting a national testing algorithm based on
evaluations performed at a single point of time or in a single
population are inadequate. While an individual test may meet
the WHO recommended threshold for specificity of at least
98% at a single location or point in time [4], our results indicate
it may not be possible to be extrapolate these results to other
sites within the same country or region, nor can they be
considered to be consistent over time. Given that even minor
changes in specificity, particularly in low prevalence contexts,
can lead to unacceptable positive predictive values, this has
major implications for policy makers and patients undergoing
HIV testing. There are important programmatic costs
associated to falsely including someone in an HIV programme,
in addition to the obvious individual costs of being falsely
diagnosed [23].
Given this, we recommend that policy-makers re-examine
the current guidance for determining and monitoring a test
algorithm. A change would be needed that involves evaluation
of algorithm performance against a gold standard at each
Variable Specificity of HIV Rapid Diagnostic Tests
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geographic test site, and regular evaluation over time of test
performance against the gold standard. An alternative
approach which is more straightforward to implement given the
serious practical challenges in implementing such a policy,
could be to include confirmation testing for all patients as is
done routinely in resource-rich settings. Incorporating
confirmation testing into the algorithm would protect against the
varying and unpredictable specificity we found in the test sites,
and allow timely transmission of accurate results to clients. In
our experience in these settings confirmation testing in the
laboratory is both feasible and affordable [23,24].
Limitations to the review include the fact that it is routinely
collected programmatic data and therefore subject to some
gaps due to missing data. Another limitation is a bias
introduced by the fact that high discordancy rates were
responded to programmatically by either changing the choice
of tests or moving to serial from parallel testing. This limits the
range of specificity change profiled in this analysis. As the data
used in the analysis is derived from discordant test results, our
model is likely to under-estimate the rate of false positivity by
excluding those samples whereby both tests are false positive.
Double false positives, whereby both tests display poor
specificity are well documented [17,24].. Finally our ability to
measure variability over time was limited by the short period of
data collection in some sites which may have underestimated
the degree of variation.
Conclusion
This analysis demonstrates the variability of specificity of
multiple independent HIV RDTs over time and geographic
location. These results suggest a higher than previously
appreciated risk of false positive HIV results using the current
WHO guidelines for testing and evaluating diagnostic
algorithms. This suggests a need to re-consider the current
guidance for choosing and monitoring HIV testing algorithm
performance in order to avoid the very significant personal and
programmatic risk of false positive HIV results. A practical way
to do this would be to incorporate a confirmation test into the
test algorithm.
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vertical scale for each plot, although credible intervals for
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